A novel approach for early cancer treatment known as radioligand therapy (RLT) has been shown to significantly reduce the risk of advanced neuroendocrine tumor progression and death, according to research led by scientists at Sunnybrook Health Sciences Centre and the University of Toronto.
Medical Xpress – latest medical and health news stories